14年后再加码！山西这家上市药企斥资近亿元拍下浙江一制药公司股权

Core Viewpoint - Shanxi-listed pharmaceutical company Qianyuan Pharmaceutical has successfully acquired a 40% stake in Qianyuan Hailisheng Pharmaceutical through a judicial auction for 155 million yuan, increasing its ownership from 60% to 80% and strengthening its control over the company [1][2][10] Group 1: Auction Details - The 40% stake was previously held by Hailisheng Group, which faced financial difficulties leading to the judicial auction [1][2] - The auction began on February 24, with an assessed value of 177 million yuan and a starting price of 124 million yuan, ultimately selling for 155 million yuan after 43 bids [2] Group 2: Company Background - Qianyuan Hailisheng, originally Zhejiang Hailisheng Pharmaceutical, has a history dating back to 1989 and specializes in natural marine drugs and chemical synthetic drugs [3] - The company has established a strong market presence with key products, including a raw material drug that captures about 20% of the national market share [6] Group 3: Strategic Implications - The acquisition is part of Qianyuan Pharmaceutical's broader strategy to enhance its core pharmaceutical assets and expand into high-tech innovative drug sectors [8] - The partnership with Zhoushan Ronghao, which is linked to the original management team of Hailisheng Group, is expected to stabilize the core team and ensure continuity in operations and strategy [6][10] Group 4: Financial Performance - In 2024, Qianyuan Hailisheng reported revenues of 309 million yuan and a net profit of 48.36 million yuan, with 2025's first three quarters showing stable performance [4][6] - The increase in ownership is anticipated to improve Qianyuan Pharmaceutical's overall operational performance and profitability [10]